AI in Healthcare

Today's Stories

1. 1

   Google Cloud tool classifies child pneumonia from X-rays without coding

   Researchers used Google Cloud Vertex AI AutoML, a no-code machine learning platform, to build and validate a system that automatically classifies pneumonia in pediatric chest radiographs (X-ray images of children's chests). The study was a proof-of-concept internal validation, published in the journal Cureus. Pneumonia diagnosis typically requires radiologist expertise and time. An automated classification system could reduce diagnostic delays and potentially expand access to reliable pneumonia detection in settings with limited specialist availability, particularly for pediatric cases where misdiagnosis carries clinical risk.

   The study represents a proof-of-concept validation; the body does not specify availability, deployment timeline, accuracy metrics, or rollout plans. Further external validation and clinical integration steps would be needed before real-world hospital use.

2. 2

   Cuban: AI Replaces Admin Work, Not Radiologists—Cost and Liability Lock In Doctors

   Mark Cuban argued on X that radiologists will not be replaced by AI because foundation models become outdated upon release, inference at clinical scale costs far more than radiologist salaries, and combining AI with medical domain knowledge is complex. He separately claimed AI will replace most doctors' administrative tasks—the paperwork introduced by large healthcare conglomerates—rather than clinical judgment. Cuban co-founded Mark Cuban Cost Plus Drug Company, which bypasses the pharmacy benefit manager (PBM) layer, so his framing reflects a specific business interest. However, the three largest PBMs—CVS Health (owner of Caremark), Cigna (owner of Express Scripts), and UnitedHealth Group (owner of Optum Rx)—are already deploying AI to automate the exact administrative work Cuban targets, raising the question of whether such automation will compress their operating margins or expand them.

   CVS reported Q2 2026 Health Services revenue of nearly $52 billion and launched an AI-enabled claims-assist manager that will reduce processing time by over 20%; Cigna reported Q2 2026 Evernorth revenue of $61.5 billion and said its Pharmacy Forward program cuts time to therapy in half and reduces clinician documentation time by up to 50%; UnitedHealth Group reported Q2 revenue of $112 billion and targets processing 80% of prior authorizations in real time by end of 2027.

3. 3

   Hospital seeks on-prem MLOps platform for production model monitoring

   A hospital operating a fully on-premises OpenShift cluster is evaluating ClearML and OpenShift AI for managing machine learning models built by multiple internal teams, as well as models running at external vendors. The organization is building a self-service platform with centralized boundary policies to let teams work independently while enforcing guardrails around access control and resource limits. Healthcare organizations must keep patient data on-premises for compliance and security reasons, ruling out cloud-based MLOps tools. The hospital's challenge—monitoring both internal models and external vendor models for production issues like data drift and bias—reflects a real constraint in regulated industries where real-time visibility across the full model lifecycle is critical for patient safety.

   The hospital has identified a gap in existing platforms: neither ClearML nor OpenShift AI provides the production monitoring depth needed (drift detection, bias tracking, live per-model dashboards). The ability to monitor vendor models where only input/output data feeds are available—a common scenario in healthcare partnerships—appears to be an unmet need in the current tooling landscape.

4. 4

   Genomics expert Schadt leaves Pathos AI, joins Pfizer as first AI Scholar

   Eric Schadt, a computational biology expert and former chief scientist at Pathos AI, is departing that role to advise Pfizer as its first AI Scholar while also launching a new stealth-mode startup. Schadt will remain Dean for Precision Medicine at the Icahn School of Medicine at Mount Sinai. Schadt is a veteran biotech entrepreneur with a track record spanning roles at Roche, Merck, Pacific Biosciences, and Sema4; he has published over 500 scientific papers with an H-Index of 165 and has appeared on lists of the world's most influential scientists. His advisory role at Pfizer signals the pharmaceutical giant is betting on AI to reshape its R&D strategy and drug discovery process.

   Schadt's stealth startup is focused on precision medicine, built on the principle of starting with individual patient data and using AI to guide treatment decisions. At Pfizer, he will work with teams to shape AI strategy and build proprietary models.

5. 5

   Eli Lilly partners with Insilico Medicine for $2.8B AI drug discovery

   Eli Lilly has signed an agreement with Hong Kong-based Insilico Medicine valued at $2.8B to expand its AI-driven drug development efforts. The deal signals that major pharmaceutical companies are increasingly betting on AI to accelerate and reduce costs in drug discovery—a traditionally slow, expensive process that historically takes years and billions to bring a single drug to market.

   The partnership will test whether AI can meaningfully shorten timelines and improve success rates in identifying drug candidates, a critical benchmark for the pharmaceutical industry's broader embrace of machine learning in research.

6. 6

   WIO 2026 conference to feature AI, AMD, physician talks

   The World Ophthalmology Congress (WIO) 2026 has announced its agenda, which will include sessions on artificial intelligence, age-related macular degeneration (AMD), and physician leadership topics. Ophthalmology conferences shape clinical practice and research priorities. A congress agenda that covers AI reflects the specialty's interest in how machine learning may influence eye care, while AMD and leadership education address pressing clinical and professional needs in the field.

   WIO 2026 will bring together ophthalmologists globally to discuss emerging tools and practice challenges, though the body does not specify dates, location, or registration details.